Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Large Decrease in Short Interest

Tiziana Life Sciences Ltd (NASDAQ:TLSA) was the recipient of a significant decrease in short interest in the month of November. As of November 30th, there was short interest totalling 208,100 shares, a decrease of 24.3% from the November 15th total of 274,900 shares. Approximately 0.3% of the shares of the stock are short sold. Based on an average trading volume of 261,300 shares, the short-interest ratio is presently 0.8 days.

Tiziana Life Sciences Price Performance

Tiziana Life Sciences stock remained flat at $0.94 during mid-day trading on Friday. The company’s stock had a trading volume of 67,138 shares, compared to its average volume of 214,483. The business has a fifty day moving average of $0.95 and a two-hundred day moving average of $0.97. Tiziana Life Sciences has a 1 year low of $0.41 and a 1 year high of $1.74.

Institutional Investors Weigh In On Tiziana Life Sciences

An institutional investor recently raised its position in Tiziana Life Sciences stock. Zhang Financial LLC raised its position in Tiziana Life Sciences Ltd (NASDAQ:TLSA) by 24.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 69,387 shares of the company’s stock after buying an additional 13,500 shares during the period. Zhang Financial LLC owned 0.07% of Tiziana Life Sciences worth $67,000 as of its most recent SEC filing.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.